1-8 of 8
Christian Klein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma

Raffaella Iurlaro, Inja Waldhauer, Ester Planas-Rigol, Ester Bonfill-Teixidor, Alexandra Arias, Valeria Nicolini, Anne Freimoser-Grundschober, Isabel Cuartas, Alba Martínez-Moreno, Francisco Martínez-Ricarte, Esteban Cordero, Marta Cicuendez, Simona Casalino, Xavier Guardia-Reyes, Linda Fahrni, Thomas Pöschinger, Virginie Steinhart, Marine Richard, Stefanie Briner, Joerg Mueller, Franz Osl, Johannes Sam, Sara Colombetti, Marina Bacac, Christian Klein, Estela Pineda, Luis Reyes-Figueroa, Alberto Di Somma, Josep González, Paolo Nuciforo, Joan Carles, Maria Vieito, Josep Tabernero, Pablo Umaña, Joan Seoane
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (10): 1499–1509.
https://doi.org/10.1158/1535-7163.MCT-22-0201
Published: 07 October 2022
View article titled, A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
Open the PDF for A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction

Ivana Spasevska, Eva Laure Matera, Kamel Chettab, Jade Ville, Marie Potier-Cartereau, Lars Petter Jordheim, Catherine Thieblemont, Denis Sahin, Christian Klein, Charles Dumontet
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (11): 2371–2381.
https://doi.org/10.1158/1535-7163.MCT-19-0839
Published: 03 November 2020
View article titled, Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction
Open the PDF for Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction in another window
Includes: Supplementary data
Journal Articles

A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells

Martina Schmittnaegel, Eike Hoffmann, Sabine Imhof-Jung, Cornelia Fischer, Georg Drabner, Guy Georges, Christian Klein, Hendrik Knoetgen
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (9): 2130–2142.
https://doi.org/10.1158/1535-7163.MCT-16-0207
Published: 01 September 2016
View article titled, A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells
Open the PDF for A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells in another window
Includes: Supplementary data
Journal Articles

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Peter Brünker, Katharina Wartha, Thomas Friess, Sandra Grau-Richards, Inja Waldhauer, Claudia Ferrara Koller, Barbara Weiser, Meher Majety, Valeria Runza, Huifeng Niu, Kathryn Packman, Ningping Feng, Sherif Daouti, Ralf J. Hosse, Ekkehard Mössner, Thomas G. Weber, Frank Herting, Werner Scheuer, Hadassah Sade, Cuiying Shao, Bin Liu, Peng Wang, Gary Xu, Suzana Vega-Harring, Christian Klein, Klaus Bosslet, Pablo Umaña
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (5): 946–957.
https://doi.org/10.1158/1535-7163.MCT-15-0647
Published: 05 May 2016
View article titled, RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
Open the PDF for RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis in another window
Includes: Supplementary data
Journal Articles

Abstract A245: Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.

Deepak Sampath, Sylvia Herter, Ellen Ingalla, Frank Herting, Marina Bacac, Michelle Nannini, Wayne J. Fairbrother, Christian Klein
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A245.
https://doi.org/10.1158/1535-7163.TARG-13-A245
Published: 01 November 2013
View article titled, Abstract A245: Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.
Journal Articles

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Sylvia Herter, Frank Herting, Olaf Mundigl, Inja Waldhauer, Tina Weinzierl, Tanja Fauti, Gunter Muth, Doris Ziegler-Landesberger, Erwin Van Puijenbroek, Sabine Lang, Minh Ngoc Duong, Lina Reslan, Christian A. Gerdes, Thomas Friess, Ute Baer, Helmut Burtscher, Michael Weidner, Charles Dumontet, Pablo Umana, Gerhard Niederfellner, Marina Bacac, Christian Klein
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2013) 12 (10): 2031–2042.
https://doi.org/10.1158/1535-7163.MCT-12-1182
Published: 07 October 2013
View article titled, Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <em>In Vitro</em> and in Xenograft Models
Open the PDF for Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <em>In Vitro</em> and in Xenograft Models in another window
Includes: Multimedia, Supplementary data
Journal Articles

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

Stephane Dalle, Lina Reslan, Timothee Besseyre de Horts, Stephanie Herveau, Frank Herting, Adriana Plesa, Thomas Friess, Pablo Umana, Christian Klein, Charles Dumontet
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (1): 178–185.
https://doi.org/10.1158/1535-7163.MCT-10-0385
Published: 10 January 2011
View article titled, Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
Open the PDF for Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101 in another window
Includes: Supplementary data
Journal Articles

Novel third generation humanized type II CD20 antibody with superior direct cell death induction and glycoengineered Fc region for enhanced ADCC induction

Pablo Umana, Ekkehard Moessner, Peter Bruenker, Gabriele Unsin, Tobias Suter, Roger Grau, Ursula Puentener, Carla Schmidt, Christian Gerdes, Adam Napora, Monika Patre, Samuel Moser, Peter Sondermann, Luise Wheat, Martin Dyer, Sibrand Poppema, Sabine Bauer, Manfred Kubbies, Pamela Strein, Georg Fertig, Thomas Friess, Christian Klein
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A56.
Published: 01 November 2007
View article titled, Novel third generation humanized type II CD20 antibody with superior direct cell death induction and glycoengineered Fc region for enhanced ADCC induction